Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br Acknowledgements br This study was supported by Basic

    2019-09-16


    Acknowledgements
    This study was supported by Basic Science Research Program through the National Research Foundation, Ministry of Science and ICT (Grant No. 2012015106) and the Global Core Research Center (GCRC) grant (No. 2011-0030001) from the National Research Foundation Republic of Korea and the GRRC program of Gyeonggi province [GRRC-kyunghee2019(B03)], Republic of Korea.
    Appendix A. Supplementary data
    References
    W.E. Grizzle, D.J. Buchsbaum, S.A. Kaliberov, Experimental cancer therapy using restoration of NAD+-linked 15-hydroxyprostaglandin dehydrogenase expression, Mol. Canc. Therapeut. 8 (2009) 3130–3139.
    [20] E.Y. Chang, Y.C. Chang, C.T. Shun, Y.W. Tien, S.H. Tsai, S.W. Hee, I.J. Chen, L.M. Chuang, Inhibition of prostaglandin reductase 2, a putative oncogene over-expressed in human pancreatic adenocarcinoma, induces oxidative stress-mediated cell death involving xCT and CTH gene expressions through 15-keto-PGE2, PLoS One 11 (2016) e0147390.
    17 Accepted Manuscript
    18F-FDG PET Predicts Hematologic Toxicity in Locally Advanced Anal Cancer Patients Treated with Chemoradiation
    John David, MD, Yong Yue, PhD, Kevin Blas, MD, Andrew Hendifar, MD, Peyman Kabolizadeh, MD, Richard Tuli, MD PhD
    To appear in: Advances in Radiation Oncology
    Please cite this article as: David J, Yue Y, Blas K, Hendifar A, Kabolizadeh P, Tuli R, 18F-FDG PET Predicts Hematologic Toxicity in Locally Advanced Anal Cancer Patients Treated with Chemoradiation, Advances in Radiation Oncology (2019), doi: https://doi.org/10.1016/j.adro.2019.06.005.
    This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it AZD-5991 is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
    ACCEPTED MANUSCRIPT
    Manuscript title:
    18F-FDG PET Predicts Hematologic Toxicity in Locally Advanced Anal Cancer Patients Treated with Chemoradiation
    Running title:
    PET predicts Hematologic Toxicity
    Authors:
    John David MD1*, Yong Yue PhD2*†, Kevin Blas MD3, Andrew Hendifar MD5, Peyman Kabolizadeh MD3, Richard Tuli MD PhD5‡
    1Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA 90048
    2Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN 46202
    3Department of Radiation Oncology, Beaumont Hospital, Royal Oak, MI 48073
    4Department of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, CA 90048
    5Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065
    *First Co-author
    †Responsible for statistical analysis
    ‡Corresponding author
    Corresponding Statistician: [email protected], Department of Radiation Oncology,
    Indiana University School of Medicine, 535 Barnhill drive, Indianapolis, IN 46202. Phone
    Correspondence: [email protected], Department of Radiation Oncology, Cedars-
    Disclosures: The authors have no conflicts of interest related to tropic hormone work
    Acknowledgments: None
    ACCEPTED MANUSCRIPT
    Financial Support: None
    ACCEPTED MANUSCRIPT
    18F-FDG PET Predicts Hematologic Toxicity in Locally Advanced Anal Cancer Patients Treated with
    Chemoradiation
    Abstract:
    Purpose: Hematologic toxicities (HT) during chemoradiotherapy (CRT) for anal cancer can lead to treatment breaks compromising efficacy. We hypothesized that CRT induced HT correlate with changes in active bone marrow (ABM) characterized by pre/post-CRT PET/CT.